Efficacy of Adjunctive Zinc in Improving the Treatment Outcomes in Hospitalized Children with Pneumonia: A Randomized Controlled Trial.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

The mortality rate of pneumonia is high, placing a huge burden on developing countries.

Healthcare professionals use zinc as an adjunctive treatment for children with pneumonia; however, this contradicts with some published reports.

Who Took Part

The age groups tagged for this paper are infants, young children and children, both men and women.

A randomized, double-blind, placebo-controlled trial was conducted on hospitalized children with pneumonia.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

Some participants received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

The primary outcome was the resolution time of pneumonia, and the secondary outcomes were the duration of hospitalization and the recovery times of each clinical symptom.

What Was Measured

PubMed files the paper under topics including Anti-Bacterial Agents, Dietary Supplements, Fever, Inpatients, Length of Stay, Pneumonia and Zinc.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2020 (Journal of tropical pediatrics), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.